BDTX vs. TRDA, DNA, ORKA, TRML, XERS, ALT, PROK, MNMD, STOK, and RNAC
Should you be buying Black Diamond Therapeutics stock or one of its competitors? The main competitors of Black Diamond Therapeutics include Entrada Therapeutics (TRDA), Ginkgo Bioworks (DNA), Oruka Therapeutics (ORKA), Tourmaline Bio (TRML), Xeris Biopharma (XERS), Altimmune (ALT), ProKidney (PROK), Mind Medicine (MindMed) (MNMD), Stoke Therapeutics (STOK), and Cartesian Therapeutics (RNAC). These companies are all part of the "pharmaceutical products" industry.
Black Diamond Therapeutics vs.
Black Diamond Therapeutics (NASDAQ:BDTX) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership, media sentiment and community ranking.
95.5% of Black Diamond Therapeutics shares are held by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are held by institutional investors. 8.9% of Black Diamond Therapeutics shares are held by company insiders. Comparatively, 7.6% of Entrada Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Entrada Therapeutics has a net margin of 25.53% compared to Black Diamond Therapeutics' net margin of 0.00%. Entrada Therapeutics' return on equity of 16.11% beat Black Diamond Therapeutics' return on equity.
Black Diamond Therapeutics has a beta of 2.49, indicating that its share price is 149% more volatile than the S&P 500. Comparatively, Entrada Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the S&P 500.
Black Diamond Therapeutics received 33 more outperform votes than Entrada Therapeutics when rated by MarketBeat users. However, 81.82% of users gave Entrada Therapeutics an outperform vote while only 69.86% of users gave Black Diamond Therapeutics an outperform vote.
Black Diamond Therapeutics presently has a consensus price target of $15.50, indicating a potential upside of 604.55%. Entrada Therapeutics has a consensus price target of $25.67, indicating a potential upside of 102.26%. Given Black Diamond Therapeutics' higher probable upside, analysts clearly believe Black Diamond Therapeutics is more favorable than Entrada Therapeutics.
Entrada Therapeutics has higher revenue and earnings than Black Diamond Therapeutics. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Black Diamond Therapeutics and Black Diamond Therapeutics both had 1 articles in the media. Entrada Therapeutics' average media sentiment score of 1.67 beat Black Diamond Therapeutics' score of 0.76 indicating that Entrada Therapeutics is being referred to more favorably in the news media.
Summary
Entrada Therapeutics beats Black Diamond Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Black Diamond Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BDTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Black Diamond Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:BDTX) was last updated on 1/21/2025 by MarketBeat.com Staff
